论文部分内容阅读
宫颈癌是女性中第二大恶性肿瘤,发病率仅次于乳腺癌。我国每年宫颈癌的新发病例和死亡数分别约为13.5万和5万[1]。而目前研究表明宫颈癌是唯一一种经过医学干预能使发病率和死亡率下降的恶性肿瘤[2]。从宫颈癌前病变发展为宫颈癌大约需要10~15年时间[3]。因此,早期筛查发现宫颈癌前病变对防治宫颈癌发生尤为关键。本文将在2008年8月~2009年12月在我院妇科门诊就诊行宫颈筛查的病例为对象,探讨液基细胞学联合人乳头瘤病毒检测用于筛查宫颈癌前病变的应用价值。
Cervical cancer is the second most common malignant tumor in women, with the second highest incidence of breast cancer. China’s annual new cases of cervical cancer and deaths were about 135,000 and 50,000 [1]. However, studies have shown that cervical cancer is the only malignant tumor that can reduce morbidity and mortality after medical intervention [2]. From cervical precancerous lesions to cervical cancer takes about 10 to 15 years [3]. Therefore, early screening found that precancerous lesions of cervical cancer prevention and treatment of cervical cancer is particularly crucial. This article will be in August 2008 ~ December 2009 in our hospital outpatient gynecological clinic cervical screening cases as the object, to explore liquid-based cytology combined with human papillomavirus test for the screening of cervical precancerous lesions of the application value.